ArticleBMC gastroenterology2026
Diagnostic performance of TyG-related indices for MAFLD screening in older adults at moderate altitude: TyG-BMI showed the highest discriminatory ability.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTriglyceride-glucose (TyG) index and its composite parameters have been proposed as surrogate indicators of insulin resistance. However, their association with metabolic dysfunction–associated fatty liver disease (MAFLD) among older adults living at moderate altitude remains insufficiently examined. The present study aims to investigate the association between TyG-related indices and MAFLD in this population and to identify the optimal screening indicator.
methodsCross-sectional data were obtained from health examinations of older adults in a community in Lanzhou, China, during 2023–2024, comprising 3,547 residents aged ≥ 65 years. Univariate and multivariable logistic regression analyses were conducted to assess the association between TyG-related indices and MAFLD. Smooth curve fitting was applied to examine potential nonlinear relationships, and a two-piecewise linear regression model was used to further characterize nonlinearity. Receiver operating characteristic (ROC) analysis was employed to evaluate the predictive value of TyG-related indices for MAFLD risk.
resultsA total of 2,986 community-dwelling adults aged ≥ 65 years from Lanzhou were included, with an overall MAFLD prevalence of 22.77%. After full adjustment for confounders, all TyG-related indices were significantly and positively associated with MAFLD risk in a dose-dependent manner. Restricted cubic spline analyses revealed significant nonlinear, J-shaped dose-response relationships for all four indices (TyG, TyG-BMI, TyG-WC, and TyG-WHtR; all P for nonlinearity < 0.05). Threshold effect analysis further identified saturation effects, particularly for TyG-BMI and TyG-WHtR, with the risk of MAFLD increasing sharply below their inflection points (266.44 and 5.59, respectively) but plateauing thereafter. Subgroup analyses revealed significant interactions. The associations of TyG-BMI, TyG-WC, and TyG-WHtR with MAFLD were stronger in males and non-diabetic participants (all P for interaction < 0.05). Receiver operating characteristic (ROC) analysis demonstrated that TyG-BMI had the best discriminative performance for MAFLD (AUC = 0.776, 95% CI: 0.757–0.795), which was statistically superior to TyG-WC (AUC = 0.737), TyG-WHtR (AUC = 0.730), and TyG (AUC = 0.672) (all P for comparison < 0.001). The optimal cut-off for TyG-BMI was 213.905, with a sensitivity of 77.1% and a specificity of 64.2%.
conclusionsIn older adults at moderate altitude, TyG-related indices demonstrated valuable diagnostic performance for MAFLD screening. TyG-BMI showed the highest discriminatory ability (AUC = 0.776), statistically outperforming TyG-WC, TyG-WHtR, and the conventional TyG index. Its screening efficacy may be more pronounced in non-diabetic individuals. Therefore, TyG-BMI can serve as a simple, superior, and non-invasive screening tool for MAFLD in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.